Fundraising Fox
/Companies
Sign in

EnPlusOne Biosciences

Watertown, US · Founded 2022 · Delaware corporation · 3 known investors

Find your way into EnPlusOne Biosciences

Sign up to see every warm intro you have to EnPlusOne Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the EnPlusOne Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications. It aims to expand the accessible RNA design space and manufacturing capacity for RNA-based drugs.

BiotechDeep Tech

Founders & leadership

EnPlusOne Biosciences was founded in 2022 by Daniel Ahlstedt and Jonathan Rittichier.

DADaniel Ahlstedt
Daniel AhlstedtCo-founder and Chief Operating OfficerHe has experience in biotechnology process engineering, manufacturing operations, equipment design, and large capital project implementation in regulated environments.
JRJonathan Rittichier
Jonathan RittichierCo-founder · Chief Scientific OfficerFounder at Enplusonebio
DW
Daniel WiegandFounder
GM
George M. ChurchFounder

Board

PMPaxton Major
Paxton MajorBoard DirectorManaging Director at Northpond Ventures
ALAndrew Lee
Andrew LeeBoard ObserverManaging Director at Northpond Ventures
SK
Steven KasokBoard director

Investors · 3

Coatue Managementlisted by Coatue ManagementNew York · $1M – $20M

How we know: funding news · press coverage · Not right? Tell us

Northpond VenturesreportedBethesda · $100K – $5Mvia Paxton Major · board

How we know: a partner's Signal profile · board seat on SEC Form D · funding news · press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$21.8M disclosed across 1 round · 2022

▶$21.8MraisedDec 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paxton MajorDirector
  • Andrew LeeDirector
  • Steven KasokDirector
  • Daniel AhlstedtExecutive Officer, Director
Offering amount
$23.1M
Amount sold
$21.8M
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

EnPlusOne Biosciences Raises $10M in Financingfinsmes.com · Feb 2025EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing - EnPlusOne Bioenplusonebio.com · Sep 2022

Frequently asked questions

What does EnPlusOne Biosciences do?
En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications. It aims to expand the accessible RNA design space and manufacturing capacity for RNA-based drugs.
Who founded EnPlusOne Biosciences?
EnPlusOne Biosciences was founded by Daniel Ahlstedt, Jonathan Rittichier in 2022.
Who are EnPlusOne Biosciences's investors?
EnPlusOne Biosciences's investors include Breakout Ventures, Coatue Management, Northpond Ventures.
How much funding has EnPlusOne Biosciences raised?
EnPlusOne Biosciences has disclosed $21.8M raised across 1 round.
Where is EnPlusOne Biosciences headquartered?
EnPlusOne Biosciences is headquartered in Watertown, US.